• 1
    Smith PH, Bono A, Debruyne F et al. Some limitations of the radioisotope bone scan in patients with metastatic prostate cancer. Cancer 1990; 66: 100916.
  • 2
    Kosuda S, Arai S, Yokoyama H et al. Differential diagnosis between osseous metastasis and degenerative joint disease of the vertebrae by bone SPECT; analysis by accumulation pattern. Jpn. J. Nucl. Med. 1994; 31: 6138.
  • 3
    Ishizuka O, Tanabe T, Nakayama T et al. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int. J. Urol. 2005; 12: 72832.
  • 4
    Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J. Urol. 2004; 171: 21227.
  • 5
    Lee N, Fawaaz R, Olsson CA et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int. J. Radiat. Oncol. Biol. Phys. 2000; 48: 14436.
  • 6
    Jacobson AF, Fogelman I. Bone scanning in clinical oncology: does it have a future? Eur. J. Nucl. Med. 1998; 25: 121923.
  • 7
    Kosuda S, Kaji T, Yokoyama H. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? J. Nucl. Med. 1996; 37: 9758.
  • 8
    Tombal B, Rezazadeh A, Therasse P et al. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005; 65: 17887.
  • 9
    Savelli G, Maffioli L, Maccauro M et al. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q. J. Nucl. Med. 2001; 45: 2737.
  • 10
    Ghanem N, Uhl M, Brink I et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur. J. Radiol. 2005; 55: 4155.